Frontal lobe bioenergetic metabolism in depressed adolescents with bipolar disorder: A phosphorus-31 magnetic resonance spectroscopy study

Bipolar Disorders

Volumn 14, Issue 6, 2012, Pages 607-617

  Shi, Xian Feng ^a   Kondo, Douglas G ^a,b   Sung, Young Hoon ^a   Hellem, Tracy L ^a   Fiedler, Kristen K ^a   Jeong, Eun Kee ^a   Huber, Rebekah S ^a   Renshaw, Perry F ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

31P MRS; Adolescent; Bipolar disorder; Depression

Indexed keywords

CREATINE PHOSPHATE; NUCLEOSIDE TRIPHOSPHATE; PHOSPHATE;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; BIOENERGY; BIPOLAR DEPRESSION; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; FEMALE; FRONTAL LOBE; HIGH ENERGY PHOSPHATE; HUMAN; MALE; NEUROCHEMISTRY; NEUROPSYCHIATRY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADOLESCENT; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DEPRESSION; ENERGY METABOLISM; FEMALE; FRONTAL LOBE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MITOCHONDRIA; PHOSPHATES; PHOSPHOCREATINE; PHOSPHORUS ISOTOPES; POLYPHOSPHATES;

EID: 84865705868     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2012.01040.x     Document Type: Article

References (113)

1. Perlis RH, Miyahara S, Marangell LB et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004; 55: 875-881.
2. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994; 31:281-294.
3. Leverich GS, Post RM, Keck PE Jr et al. The poor prognosis of childhood-onset bipolar disorder. J Pediatr 2007; 150: 485-490.
4. Gore FM, Bloem PJ, Patton GC et al. Global burden of disease in young people aged 10-24years: a systematic analysis. Lancet 2011; 377: 2093-2102.
5. Post RM, Kowatch RA. The health care crisis of childhood-onset bipolar illness: some recommendations for its amelioration. J Clin Psychiatry 2006; 67: 115-125.
6. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorder and Recurrent Depression. 2nd ed. New York: Oxford University Press, 2007.
7. Belmaker RH, Agam G. Bipolar disorder: neurochemistry and drug mechanisms. Discov Med 2005; 5: 191-198.
8. Carlson GA, Findling RL, Post RM et al. AACAP 2006 Research forum-advancing research in early-onset bipolar disorder: barriers and suggestions. J Child Adolesc Psychopharmacol 2009; 19: 3-12.
9. Insel TR. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry 2009; 66: 128-133.
10. Kupfer DJ, First MB, Regier DA. A Research Agenda for DSM-V. Arlington: American Psychiatric Publishing, 2002.
11. Phillips ML, Vieta E. Identifying functional neuroimaging biomarkers of bipolar disorder: toward DSM-V. Schizophr Bull 2007; 33: 893-904.
12. Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2000; 3: 180-190.
13. Kato T, Kunugi H, Nanko S, Kato N. Association of bipolar disorder with the 5178 polymorphism in mitochondrial DNA. Am J Med Genet 2000; 96: 182-186.
14. Kato T. Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium 2008; 44: 92-102.
15. Washizuka S, Kakiuchi C, Mori K et al. Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2003; 120B: 72-78.
16. Siciliano G, Tessa A, Petrini S et al. Autosomal dominant external ophthalmoplegia and bipolar affective disorder associated with a mutation in the ANT1 gene. Neuromuscul Disord 2003; 13: 162-165.
17. Mancuso M, Filosto M, Bellan M et al. POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness. Neurology 2004; 62: 316-318.
18. McMahon FJ, Stine OC, Meyers DA, Simpson SG, DePaulo JR. Patterns of maternal transmission in bipolar affective disorder. Am J Hum Genet 1995; 56: 1277-1286.
19. Munakata K, Fujii K, Nanko S, Kunugi H, Kato T. Sequence and functional analyses of mtDNA in a maternally inherited family with bipolar disorder and depression. Mutat Res 2007; 617: 119-124.
20. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004; 61: 300-308.
21. Kvajo M, Dhilla A, Swor DE, Karayiorgou M, Gogos JA. Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Mol Psychiatry 2008; 13: 685-696.
22. Konradi C, Sillivan SE, Clay HB. Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiol Dis 2012; 45: 37-47.
23. Pennington K, Beasley CL, Dicker P et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 2008; 13: 1102-1117.
24. Modica-Napolitano JS, Renshaw PF. Ethanolamine and phosphoethanolamine inhibit mitochondrial function in vitro: implications for mitochondrial dysfunction hypothesis in depression and bipolar disorder. Biol Psychiatry 2004; 55: 273-277.
25. Cui J, Shao L, Young LT, Wang JF. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007; 144: 1447-1453.
26. Bachmann RF, Wang Y, Yuan P et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 2009; 12: 805-822.
27. Regenold WT, Phatak P, Marano CM, Sassan A, Conley RR, Kling MA. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol Psychiatry 2009; 65: 489-494.
28. Båve U, Nybom R, Landén M, Wetterberg L. Micrometer-sized thread-like and/or spherical particles in the first fraction of cerebrospinal fluid in patients with bipolar disorder. Bipolar Disord 2010; 12: 298-305.
29. Sun X, Wang JF, Tseng M, Young LT. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci 2006; 31: 189-196.
30. Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010; 67: 360-368.
31. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005; 14: 241-253.
32. Kubota M, Kasahara T, Nakamura T, Ishiwata M, Miyauchi T, Kato T. Abnormal Ca2+ dynamics in transgenic mice with neuron-specific mitochondrial DNA defects. J Neurosci 2006; 26: 12314-12324.
33. Kasahara T, Kubota M, Miyauchi T et al. Mice with neuron-specific accumulation of mitochondrial DNA mutations show mood disorder-like phenotypes. Mol Psychiatry 2006; 11: 577-593.
34. Valvassori SS, Rezin GT, Ferreira CL et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J Psychiatr Res 2010; 44: 903-909.
35. Riegel RE, Valvassori SS, Elias G et al. Animal model of mania induced by ouabain: evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochem Int 2009; 55: 491-495.
36. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005; 10: 900-919.
37. Dager SR, Corrigan NM, Richards TL, Posse S. Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders. Top Magn Reson Imaging 2008; 19: 81-96.
38. Zhu XH, Du F, Zhang N et al. Advanced in vivo heteronuclear MRS approaches for studying brain bioenergetics driven by mitochondria. Methods Mol Biol 2009; 489: 317-357.
39. Phillips ML, Travis MJ, Fagiolini A, Kupfer DJ. Medication effects in neuroimaging studies of bipolar disorder. Am J Psychiatry 2008; 165: 313-320.
40. Pan L, Keener MT, Hassel S, Phillips ML. Functional neuroimaging studies of bipolar disorder: examining the wide clinical spectrum in the search for disease endophenotypes. Int Rev Psychiatry 2009; 21: 368-379.
41. Yurgelun-Todd DA, Ross AJ. Functional magnetic resonance imaging studies in bipolar disorder. CNS Spectr 2006; 11: 287-297.
42. Marsh R, Gerber AJ, Peterson BS. Neuroimaging studies of normal brain development and their relevance for understanding childhood neuropsychiatric disorders. J Am Acad Child Adolesc Psychiatry 2008; 47: 1233-1251.
43. Delbello MP, Strakowski SM. Neurochemical predictors of response to pharmacologic treatments for bipolar disorder. Curr Psychiatry Rep 2004; 6: 466-472.
44. Savitz J, Nugent AC, Bogers W et al. Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage 2010; 49: 2966-2976.
45. Caetano SC, Olvera RL, Hatch JP et al. Lower N-acetyl-aspartate levels in prefrontal cortices in pediatric bipolar disorder: a (1)H magnetic resonance spectroscopy study. J Am Acad Child Adolesc Psychiatry 2011; 50: 85-94.
46. Bearden CE, Glahn DC, Caetano S et al. Evidence for disruption in prefrontal cortical functions in juvenile bipolar disorder. Bipolar Disord 2007; 9(Suppl. 1): 145-159.
47. Dickstein DP, Finger EC, Skup M, Pine DS, Blair JR, Leibenluft E. Altered neural function in pediatric bipolar disorder during reversal learning. Bipolar Disord 2010; 12: 707-719.
48. Baloch HA, Hatch JP, Olvera RL et al. Morphology of the subgenual prefrontal cortex in pediatric bipolar disorder. J Psychiatr Res 2010; 44: 1106-1110.
49. Pavuluri MN, Passarotti AM, Harral EM, Sweeney JA. Enhanced prefrontal function with pharmacotherapy on a response inhibition task in adolescent bipolar disorder. J Clin Psychiatry 2010; 71: 1526-1534.
50. Chang K, Adleman N, Dienes K, Barnea-Goraly N, Reiss A, Ketter T. Decreased N-acetylaspartate in children with familial bipolar disorder. Biol Psychiatry 2003; 53: 1059-1065.
51. Patel NC, Cecil KM, Strakowski SM, Adler CM, DelBello MP. Neurochemical alterations in adolescent bipolar depression: a proton magnetic resonance spectroscopy pilot study of the prefrontal cortex. J Child Adolesc Psychopharmacol 2008; 18: 623-627.
52. Cecil KM, DelBello MP, Morey R, Strakowski SM. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord 2002; 4: 357-365.
53. Olvera RL, Caetano SC, Fonseca M et al. Low levels of N-acetyl aspartate in the left dorsolateral prefrontal cortex of pediatric bipolar patients. J Child Adolesc Psychopharmacol 2007; 17: 461-473.
54. Patel NC, DelBello MP, Cecil KM et al. Lithium treatment effects on Myo-inositol in adolescents with bipolar depression. Biol Psychiatry 2006; 60: 998-1004.
55. Patel NC, DelBello MP, Bryan HS et al. Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45: 289-297.
56. Sassi RB, Stanley JA, Axelson D et al. Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients. Am J Psychiatry 2005; 162: 2109-2115.
57. Kato T, Takahashi S, Shioiri T, Inubushi T. Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. J Affect Disord 1993; 27: 53-59.
58. Kato T, Takahashi S, Shioiri T, Murashita J, Hamakawa H, Inubushi T. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1994; 31: 125-133.
59. Deicken RF, Fein G, Weiner MW. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. Am J Psychiatry 1995; 152: 915-918.
60. Kato T, Shioiri T, Murashita J et al. Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase-encoded 31P-MRS. Psychol Med 1995; 25: 557-566.
61. Hamakawa H, Murashita J, Yamada N, Inubushi T, Kato N, Kato T. Reduced intracellular pH in the basal ganglia and whole brain measured by 31P-MRS in bipolar disorder. Psychiatry Clin Neurosci 2004; 58: 82-88.
62. Kondo DG, Sung YH, Hellem TL et al. Open-label uridine for treatment of depressed adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2011; 21: 171-175.
63. Poznanski EO, Mokros HB. Children's Depression Rating Scale, Revised (CDRS-R) Manual. Los Angeles: Western Psychological Services, 1996.
64. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
65. Kaufman J, Birmaher B, Brent D et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980-988.
66. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997; 129: 35-43.
67. Naressi A, Couturier C, Devos JM et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001; 12: 141-152.
68. Petroff OA, Prichard JW, Behar KL, Alger JR, den Hollander JA, Shulman RG. Cerebral intracellular pH by 31P nuclear magnetic resonance spectroscopy. Neurology 1985; 35: 781-788.
69. Kramer CY. Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 1956; 12: 307-310.
70. Tukey JW. The philosophy of multiple comparisons. Stat Sci 1991; 6: 100-116.
71. Yildiz A, Sachs GS, Dorer DJ, Renshaw PF. 31P Nuclear magnetic resonance spectroscopy findings in bipolar illness: a meta-analysis. Psychiatry Res 2001; 106:181-191.
72. Cerullo MA, Adler CM, Delbello MP, Strakowski SM. The functional neuroanatomy of bipolar disorder. Int Rev Psychiatry 2009; 21: 314-322.
73. Kempton MJ, Geddes JR, Ettinger U, Williams SC, Grasby PM. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 2008; 65: 1017-1032.
74. Hallahan B, Newell J, Soares JC et al. Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data. Biol Psychiatry 2011; 69: 326-335.
75. Chen CH, Suckling J, Lennox BR, Ooi C, Bullmore ET. A quantitative meta-analysis of fMRI studies in bipolar disorder. Bipolar Disord 2011; 13: 1-15.
76. Brennan BP, Hudson JI, Jensen JE et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology 2010; 35: 834-846.
77. Yildiz A, Moore CM, Sachs GS et al. Lithium-induced alterations in nucleoside triphosphate levels in human brain: a proton-decoupled 31P magnetic resonance spectroscopy study. Psychiatry Res 2005; 138: 51-59.
78. Yoon SJ, Lyoo IK, Kim HJ et al. Neurochemical alterations in methamphetamine-dependent patients treated with cytidine-5'-diphosphate choline: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2010; 35: 1165-1173.
79. Forester BP, Finn CT, Berlow YA, Wardrop M, Renshaw PF, Moore CM. Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study. Bipolar Disord 2008; 10: 691-700.
80. Jensen JE, Daniels M, Haws C et al. Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients. Exp Clin Psychopharmacol 2008; 16: 199-206.
81. Moore CM, Biederman J, Wozniak J et al. Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex. J Affect Disord 2007; 99: 19-25.
82. Lyoo IK, Dager SR, Kim JE et al. Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsychopharmacology 2010; 35: 1743-1750.
83. Germana C, Kempton MJ, Sarnicola A et al. The effects of lithium and anticonvulsants on brain structure in bipolar disorder. Acta Psychiatr Scand 2010; 122: 481-487.
84. Patel NC, DelBello MP, Cecil KM, Stanford KE, Adler CM, Strakowski SM. Temporal change in N-acetyl-aspartate concentrations in adolescents with bipolar depression treated with lithium. J Child Adolesc Psychopharmacol 2008; 18: 132-139.
85. Brambilla P, Stanley JA, Nicoletti MA et al. 1H magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in bipolar disorder patients. J Affect Disord 2005; 86: 61-67.
86. Giedd JN. Linking adolescent sleep, brain maturation, and behavior. J Adolesc Health 2009; 45: 319-320.
87. Kato T, Takahashi S, Shioiri T, Inubushi T. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 1992; 26: 223-230.
88. Brazy PC, Mandel LJ. Does availability of inorganic phosphate regulate cellular oxidative metabolism? News Physiol Sci 1986; 1: 100-103.
89. Chance B, Leigh JS Jr, Kent J et al. Multiple controls of oxidative metabolism in living tissues as studied by phosphorus magnetic resonance. Proc Natl Acad Sci U S A 1986; 83: 9458-9462.
90. Bose S, French S, Evans FJ, Joubert F, Balaban RS. Metabolic network control of oxidative phosphorylation: multiple roles of inorganic phosphate. J Biol Chem 2003; 278: 39155-39165.
91. Freeman D, Bartlett S, Radda G, Ross B. Energetics of sodium transport in the kidney. Saturation transfer 31P-NMR. Biochim Biophys Acta 1983; 762: 325-336.
92. Iles RA, Stevens AN, Griffiths JR, Morris PG. Phosphorylation status of liver by 31P-n.m.r. spectroscopy, and its implications for metabolic control. A comparison of 31P-n.m.r. spectroscopy (in vivo and in vitro) with chemical and enzymic determinations of ATP, ADP and Pi. Biochem J 1985; 229: 141-151.
93. Balaban RS. Regulation of oxidative phosphorylation in the mammalian cell. Am J Physiol 1990; 258: C377-C389.
94. Brown GC. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 1992; 284: 1-13.
95. Iotti S, Lodi R, Gottardi G, Zaniol P, Barbiroli B. Inorganic phosphate is transported into mitochondria in the absence of ATP biosynthesis: an in vivo 31P NMR study in the human skeletal muscle. Biochem Biophys Res Commun 1996; 225: 191-194.
96. Glinn M, Ni B, Paul SM. Inorganic phosphate enhances phosphonucleotide concentrations in cultured fetal rat cortical neurons. Brain Res 1997; 757: 85-92.
97. From AH, Zimmer SD, Michurski SP et al. Regulation of the oxidative phosphorylation rate in the intact cell. Biochemistry 1990; 29: 3731-3743.
98. Zhang J, Shorr L, Yoshiyama M et al. Hyperperfusion and cardioplegia effects on myocardial high-energy phosphate distribution and energy expenditure. Am J Physiol 1994; 267: H894-H904.
99. Apell HJ, Roudna M, Corrie JE, Trentham DR. Kinetics of the phosphorylation of Na, K-ATPase by inorganic phosphate detected by a fluorescence method. Biochemistry 1996; 35: 10922-10930.
100. Gatto C, Helms JB, Prasse MC, Arnett KL, Milanick MA. Kinetic characterization of tetrapropylammonium inhibition reveals how ATP and Pi alter access to the Na+-K+-ATPase transport site. Am J Physiol Cell Physiol 2005; 289: C302-C311.
101. Pedemonte CH, Beauge L. Inhibition of (Na+, K+)-ATPase by magnesium ions and inorganic phosphate and release of these ligands in the cycles of ATP hydrolysis. Biochim Biophys Acta 1983; 748: 245-253.
102. Stein WD. Energetics and the design principles of the Na/K-ATPase. J Theor Biol 1990; 147: 145-159.
103. Beauge L. Breakdown of Na+/K+-exchanging ATPase phosphoenzymes formed from ATP and from inorganic phosphate during Na+-ATPase activity. Eur J Biochem 2001; 268: 5627-5632.
104. Looney SW, el-Mallakh RS. Meta-analysis of erythrocyte Na, K-ATPase activity in bipolar illness. Depress Anxiety 1997; 5: 53-65.
105. Coppen A, Shaw DM, Malleson A, Costain R. Mineral metabolism in mania. Br Med J 1966; 1: 71-75.
106. Goldstein I, Lerer E, Laiba E et al. Association between sodium- and potassium-activated adenosine triphosphatase alpha isoforms and bipolar disorders. Biol Psychiatry 2009; 65: 985-991.
107. Mynett-Johnson L, Murphy V, McCormack J et al. Evidence for an allelic association between bipolar disorder and a Na+, K+ adenosine triphosphatase alpha subunit gene (ATP1A3). Biol Psychiatry 1998; 44: 47-51.
108. Wood AJ, Smith CE, Clarke EE, Cowen PJ, Aronson JK, Grahame-Smith DG. Altered in vitro adaptive responses of lymphocyte Na+, K(+)-ATPase in patients with manic depressive psychosis. J Affect Disord 1991; 21: 199-206.
109. Kirshenbaum GS, Saltzman K, Rose B, Petersen J, Vilsen B, Roder JC. Decreased neuronal Na(+), K(+) -ATPase activity in Atp1a3 heterozygous mice increases susceptibility to depression-like endophenotypes by chronic variable stress. Genes Brain Behav 2011; 10: 542-550.
110. Traub N, Lichtstein D. The mood cycle hypothesis: possible involvement of steroid hormones in mood regulation by means of Na+, K+-ATPase inhibition. J Basic Clin Physiol Pharmacol 2000; 11: 375-394.
111. Bagrov YY, Manusova NB, Egorova IA, Fedorova OV, Bagrov AY. Endogenous digitalis-like ligands and Na/KATPase inhibition in experimental diabetes mellitus. Front Biosci 2005; 10: 2257-2262.
112. Goldstein I, Levy T, Galili D et al. Involvement of Na(+), K(+)-ATPase and endogenous digitalis-like compounds in depressive disorders. Biol Psychiatry 2006; 60: 491-499.
113. Goldstein I, Lax E, Gispan-Herman I et al. Neutralization of endogenous digitalis-like compounds alters catecholamines metabolism in the brain and elicits anti-depressive behavior. Eur Neuropsychopharmacol 2012; 22: 72-79.